Class / Patent application number | Description | Number of patent applications / Date published |
514502000 | Iron | 31 |
20090170933 | METHOD FOR REMOVING A MEDICAL DEVICE FROM A SPASMODIC CONSTRICTION IN A BODILY PASSAGEWAY - A method and apparatus for removing a medical device entrapped in a bodily passageway resulting from a spasmodic constriction of bodily tissue surrounding the device involves delivering to the site of the constriction an amount of an antispasmodic agent sufficient to relax the surrounding bodily tissue. The method may also be used for relaxing the tissue of a vessel wall to inhibit constriction of the vessel wall upon the introduction of a medical device into the vessel. | 07-02-2009 |
20090186939 | Method of Treating Chronic Kidney Disease - The present invention discloses pharmaceutical-grade ferric organic compounds having enhanced dissolution rate. These ferric organic compounds, including but are not limited to ferric citrate, are useful for treating chronic kidney disease. | 07-23-2009 |
20090326060 | Method of Reversing, Preventing, Delaying or Stabilizing Soft Tissue Calcification - The present invention provides methods of treating soft tissue calcification in a subject, comprising a step of administering to said subject an effective amount of ferric organic compound, such as ferric citrate. The claimed methods may prevent, reverse, delay or stabilize soft tissue calcification in a subject having chronic kidney disease. Affected soft tissue calcification includes soft tissue calcification in the joint, skin, eye, in cardiovascular system such as heart valve, myocardium, coronary arteries and arteriole, or in internal organs such as kidney and lung. | 12-31-2009 |
20090326061 | APOPTOTIC AND ANTI-TUMOR ACTIVITIES OF METALLO-SALENS - The present invention describes the synthesis and biochemical activities of metallo-salen compounds and their derivatives. The Mn(III)-salen and Fe(III)-salen derivatives of the present invention are potential anti-tumor agents, that affect cell viability, induce strong apoptotic activity, cause nuclear condensation, fragmentation, and ultimately death in breast cancer cells MCF-7. | 12-31-2009 |
20100190850 | WATER-SOLUBLE BINUCLEAR NITROSYL IRON COMPLEXES WITH NATURAL ALIPHATIC THIOLYLS POSSESSING CYTOTOXIC, APOPTOTIC AND NO-DONOR ACTIVITY - The present invention relates to water-soluble binuclear cationic nitrosyl iron complexes with natural aliphatic thiolyls of general formula [Fe | 07-29-2010 |
20110015263 | THERAPEUTIC DELIVERY OF CARBON MONOXIDE - Compounds, pharmaceutical compositions and methods for the therapeutic delivery of carbon monoxide to humans and other mammals that employ transition metal complexes having at least a substituted cyclopentadienyl, indenyl or fluorenyl ligand and two or more carbonyl ligands. | 01-20-2011 |
20110021629 | IRON PREPARATION SUITABLE FOR PHARMACEUTICAL FORMULATION AND PROCESS FOR THE PREPARATION THEREOF - New iron preparations comprising stable, unpolymerized iron(III) citrate complex compositions and methods for their preparation are provided. Further, the invention involves the use stable, unpolymerized iron(III) citrate complex compositions of the invention as a food additive, nutritional supplement, dietary supplement, medical food, nutrient, iron fortificant, and source of iron in the fields of nutrition for humans, animals, fish, and birds and of diagnostics. The invention further involves the use of stable, unpolymerized iron(III) citrate complex compositions of the invention as a pharmaceutical and pharmacologically active ingredient for human clinical and veterinary applications. | 01-27-2011 |
20110060041 | METHOD OF REVERSING, PREVENTING, DELAYING OR STABILIZING SOFT TISSUE CALCIFICATION - The present invention provides methods of treating soft tissue calcification in a subject, comprising a step of administering to said subject an effective amount of ferric organic compound, such as ferric citrate. The claimed methods may prevent, reverse, delay or stabilize soft tissue calcification in a subject having chronic kidney disease. Affected soft tissue calcification includes soft tissue calcification in the joint, skin, eye, in cardiovascular system such as heart valve, myocardium, coronary arteries and arteriole, or in internal organs such as kidney and lung. | 03-10-2011 |
20110060042 | EXTERNAL PREPARATION FOR SKIN - The present invention provides an external preparation for skin which contains 5-aminolevulinic acids as active components and which is excellent in skin-beautifying effects such as prevention/amelioration of skin roughness, dry skin, wrinkles, sagging and flecks of skin, and improvement of turnover of corneum; and in an ameliorating effect on skin diseases such as atopic dermatitis. An external preparation for skin which contains one or more compounds selected from the group consisting of 5-aminolevulinic acid, its salt and a derivative of them; and an iron compound; as active components, is used. | 03-10-2011 |
20110065787 | THERAPEUTIC AGENT FOR MALE STERILITY - The present invention is intended to provide an agent for treating male infertility which is highly effective to male infertility, and having few side effects. To achieve the object, an agent for treating male infertility comprising δ-amino levulinic acid shown by general formula (1), its derivative or salt thereof: | 03-17-2011 |
20110190391 | FERROCENE DERIVATIVES WITH ANTICANCER ACTIVITY - The present invention relates to compounds of the following formula (I): | 08-04-2011 |
20110196033 | PROPHYLACTIC/AMELIORATING AGENT FOR ADULT DISEASES COMPRISING 5-AMINOLEVULINIC ACID, DERIVATIVE OF 5-AMINOLEVULINIC ACID, OR SALT OF 5-AMINOLEVULINIC ACID OR THE DERIVATIVE OR 5-AMINOLEVULINIC ACID AS ACTIVE INGREDIENT - It is to provide a pharmaceutical composition which is different from an existing therapeutic agent of an adult disease, of a biochemical reaction-inhibiting type, and which action mechanism is to improve the basal metabolism, wherein the composition has no side effects, and does not generate drug resistance against adult disease; and a method for preventing/treating an adult disease by using the same. It is to provide a composition for preventing/ameliorating an adult disease such as metabolic syndrome, diabetes, hyperlipidemia, hypertension, impaired liver function, renal failure, adiposity, erectile dysfunction, menopausal disorder, shoulder discomfort, and low back pain, comprising 5-aminolevulinic acid (ALA), its derivative, or salt thereof, preferably comprising ALA, its derivative, or salt thereof, and an iron compound such as sodium ferrous citrate, iron sodium citrate and iron ammonium citrate; a food or food material for preventing/ameliorating an adult disease comprising the composition; and a method for using the composition for preparing an agent for preventing/ameliorating an adult disease. | 08-11-2011 |
20120115945 | FERRIC CITRATE DOSAGE FORMS - The disclosure relates to ferric citrate tablets and dosage forms. | 05-10-2012 |
20120122974 | HAIR RESTORER - The object of the present invention is to provide a hair restorer which exhibits a stimulatory effect on hair restoration against hair loss, hair thinning, split ends, hair graying, etc., with higher stability and safety than those of known hair restorers containing 5-aminolevulinic acids as active components. By using 5-aminolevulinic acid or its salt or its derivative, and a composition containing iron sodium diethylenetriaminepentaacetate or iron ammonium diethylenetriaminepentaacetate as active components, a hair restorer and a method for restoring hair which are excellent in hair growth promotion, and stability and safety, are provided. | 05-17-2012 |
20120142770 | PHARMACEUTICAL COMPOSITIONS OF HDAC INHIBITORS AND CHELATABLE METAL COMPOUNDS, AND METAL-HDAC INHIBITOR CHELATE COMPLEXES - The present invention provides pharmaceutical compositions of an HDAC inhibitor and a chelatable metal compound. In one embodiment, the invention provides a method of treating cancer and alleviating the side effects of the HDAC inhibitor by administering the pharmaceutical composition. In another embodiment, the present invention also provides pharmaceutical compositions of metal HDAC inhibitor chelate complexes. In another embodiment, the invention provides methods of treating cancer by administering the pharmaceutical compositions. The invention provides crystalline compositions of metal HDAC inhibitor chelate complexes and methods of producing same. | 06-07-2012 |
20120238622 | IRON (III) CITRATE, SUBSTANTIALLY FREE OF BETA-IRON HYDROXIDE OXIDE - This invention provides a method for producing high-purity iron(III) citrate substantially free of beta-iron hydroxide oxide, high-purity iron(III) citrate substantially free of beta-iron hydroxide oxide, and medical uses thereof. | 09-20-2012 |
20130274328 | FERRIC CITRATE DOSAGE FORMS - Disclosed herein are ferric citrate-containing tablets. In various embodiments, the tablets include ferric citrate formulations that meet certain dissolution, tableting and disintegration standards. In various aspects, the tablet formulations can include ferric citrate as the active ingredient and a binder. The formulations also can include a lubricant and/or a disintegrant (which, in some embodiments, can be the same as the binder). | 10-17-2013 |
20130345303 | USE OF FERRIC CITRATE IN THE TREATMENT OF CHRONIC KIDNEY DISEASE PATIENTS - Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients, are disclosed. | 12-26-2013 |
20140011872 | FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME - The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy. | 01-09-2014 |
20140018420 | FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME - The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy. | 01-16-2014 |
20140249217 | ENHANCER OF SURVIVAL OF TRANSPLANTED ORGAN - The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate. | 09-04-2014 |
20140256806 | PROPHYLACTIC AGENT FOR CHRONIC KIDNEY DISEASE - A method for ameliorating and/or preventing chronic kidney disease includes administering to a subject in need thereof an agent containing 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt thereof as an active ingredient. Preferably, these ALAs contain a metal-containing compound, such as sodium ferrous citrate. The above-mentioned ALAs, ALA; various esters, such as ALA methylester, ALA ethylester, ALA propylester, ALA butylester, and ALA pentylester; and hydrochlorides, phosphates, and sulfates, and the like of these ALA esters are preferred examples. | 09-11-2014 |
20140288172 | ERYTHROPOIETIN PRODUCTION-PROMOTING AGENT - A therapeutic and/or prophylactic agent for renal anemia comprising ALAs and an erythropoietin production promoter comprising ALAs. | 09-25-2014 |
20140288173 | ANEMIA OF CANCER IMPROVING/PROPHYLACTIC AGENT - A method for ameliorating and/or preventing cancerous anemia includes administering to a subject in need thereof an agent containing 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt thereof. Preferably, these ALAs contain a metal-containing compound, such as sodium ferrous citrate. The above-mentioned ALAs, ALA; various esters such as ALA methylester, ALA ethylester, ALA propylester, ALA butylester, and ALA pentylester; and hydrochlorides, phosphates, and sulfates, and the like of these ALA esters are preferred examples. | 09-25-2014 |
20140309298 | PHARMACEUTICAL-GRADE FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME - The present invention discloses a pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels. | 10-16-2014 |
20140323566 | SELF-MAGNETIC METAL-SALEN COMPLEX COMPOUND - A new self-magnetic metal-salen complex compound and its derivatives are provided. The present invention is a metal-salen complex compound including any one of the following compounds. | 10-30-2014 |
20150025138 | IRON (III) CITRATE, SUBSTANTIALLY FREE OF BETA-IRON HYDROXIDE OXIDE - This invention provides a method for producing high-purity iron(III) citrate substantially free of beta-iron hydroxide oxide, high-purity iron(III) citrate substantially free of beta-iron hydroxide oxide, and medical uses thereof. | 01-22-2015 |
20150065569 | METHOD FOR CANCER TREATMENT - The present invention is related to a method for cancer treatment comprising a step of administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising ferrous amino acid chelate and a pharmaceutically acceptable carrier. By means of amino acid chelating to ferrous and maintaining chelating state through the stomach, the pharmaceutical composition in accordance with the present invention would not cause any weight variation, and is suitable for inhibiting or treating cancer. | 03-05-2015 |
20150290159 | PROPHYLACTIC/AMELIORATING AGENT FOR ADULT DISEASES COMPRISING 5-AMINOLEVULINIC ACID, DERIVATIVE OF 5-AMINOLEVULINIC ACID, OR SALT OF 5-AMINOLEVULINIC ACID OR THE DERIVATIVE OF 5-AMINOLEVULINIC ACID AS ACTIVE INGREDIENT - A pharmaceutical composition which is different from an existing therapeutic agent of an adult disease, of a biochemical reaction-inhibiting type, and which action mechanism is to improve the basal metabolism, wherein the composition has no side effects, and does not generate drug resistance against adult disease; and a method for preventing/treating an adult disease by using the same. A composition for preventing/ameliorating an adult disease such as metabolic syndrome, diabetes, hyperlipidemia, hypertension, impaired liver function, renal failure, adiposity, erectile dysfunction, menopausal disorder, shoulder discomfort, and low back pain, comprising 5-aminolevulinic acid (ALA), its derivative, or salt thereof, preferably comprising ALA, its derivative, or salt thereof, and an iron compound such as sodium ferrous citrate, iron sodium citrate and iron ammonium citrate; a food or food material for preventing/ameliorating an adult disease comprising the composition; and a method for using the composition for preparing an agent for preventing/ameliorating an adult disease. | 10-15-2015 |
20160095878 | PHARMACEUTICAL-GRADE FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME - The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels. | 04-07-2016 |
20170231945 | REDUCTION OF GASTROINTESTINAL TRACT COLONISATION BY CAMPYLOBACTER | 08-17-2017 |